Idiopathic Pulmonary Fibrosis Treatment Market Size (7MM) was ~USD 3,300 million in 2023 and is projected to increase by 2034, estimates DelveInsight

DelveInsight's report titled "Idiopathic Pulmonary Fibrosis Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of burns, historical and forecasted epidemiology, as well as the Idiopathic Pulmonary Fibrosis therapeutics market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Unlock key insights into the Idiopathic Pulmonary Fibrosis Market! Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Idiopathic Pulmonary Fibrosis Therapeutics Market Outlook [https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Idiopathic Pulmonary Fibrosis Market Report

* In April 2025, Tvardi Therapeutics a nnounced a study is to evaluate the safety and tolerability of oral daily administration of TTI-101 over a 12-week treatment duration in participants with idiopathic pulmonary fibrosis (IPF).
* In April 2025, GlaxoSmithKline announced a study will assess the safety and effectiveness of GSK3915393 in IPF participants. Idiopathic Pulmonary Fibrosis is a chronic lung disease which causes scarring of the lungs and difficulty in breathing. GSK3915393 is a new medicine, which is being tested in participants with IPF for the first time.
* In April 2025, Boehringer Ingelheim announced a study is open to adults 40 years or older with idiopathic pulmonary fibrosis (IPF). People can join the study if they are not on any treatment for IPF are on stable treatment for at least 3 months before starting the study. The purpose of this study is to find out whether a medicine called BI 1819479 helps people with IPF. 3 different doses of BI 1819479 are tested in this study.
* According to DevelInsight analysis, the estimated total diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis in the 7MM were approximately 193,000 in 2023; this number is expected to increase in the future due to aging populations and improved diagnostic techniques.
* In 2023, among the 7MM, the US accounted for the highest diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis with approximately 95,000 cases. These cases are expected to increase during the forecast period (2024-2034).
* Among the EU4 and the UK, Germany had the highest diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis with nearly 21,000 cases, followed by the UK, and France with approximately 15,700, and 15,500 diagnosed prevalent cases respectively.
* In 2023, the prevalence of idiopathic pulmonary fibrosis in the 7MM was distributed as follows: mild (FVC >75%) with 55,926 cases, moderate (FVC 50%-75%) with 96,424 cases, and severe (FVC



This release was published on openPR.